Abstract-The (pro)renin receptor is a newly discovered member of the brain renin-angiotensin system. To investigate the role of brain (pro)renin receptor in hypertension, adeno-associated virus-mediated (pro)renin receptor short hairpin RNA was used to knockdown (pro)renin receptor expression in the brain of nontransgenic normotensive and human renin-angiotensinogen double-transgenic hypertensive mice. Blood pressure was monitored using implanted telemetric probes in conscious animals. Real-time PCR and immunostaining were performed to determine (pro)renin receptor, angiotensin II type 1 receptor, and vasopressin mRNA levels. Plasma vasopressin levels were determined by ELISA. Double-transgenic mice exhibited higher blood pressure, elevated cardiac and vascular sympathetic tone, and impaired spontaneous baroreflex sensitivity. Intracerebroventricular delivery of (pro)renin receptor short-hairpin RNA significantly reduced blood pressure, cardiac and vasomotor sympathetic tone, and improved baroreflex sensitivity compared with the control virus treatment in double-transgenic mice. (Pro)renin receptor knockdown significantly reduced angiotensin II type 1 receptor and vasopressin levels in double-transgenic mice. These data indicate that (pro)renin receptor knockdown in the brain attenuates angiotensin II-dependent hypertension and is associated with a decrease in sympathetic tone and an improvement of the baroreflex sensitivity. In addition, brain-targeted (pro)renin receptor knockdown is associated with downregulation of angiotensin II type 1 receptor and vasopressin levels. We conclude that central (pro)renin receptor contributes to the pathogenesis of hypertension in human renin-angiotensinogen transgenic mice.
Animal
Human renin and human angiotensinogen transgenic mice were generated at the University of Iowa Transgenic Animal Facilities (a generous gift from Dr Curt D. Sigmund). Double-transgenic mice (RA) expressing both human renin and AGT transgenes were generated by breeding human renin mice with human angiotensinogen mice. RA mice and nontransgenic (NT) littermates were used in this study. All of the procedures were conducted in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committees at Tulane University School of Medicine.
Construction and Production of Adeno-Associated Virus-PRR-Short-Hairpin RNA
Short-hairpin RNA (shRNA) was designed to target mRNA encoding for mouse PRR. Targets were ligated and cloned into an adeno-associated virus 2 vector tagged with green fluorescent protein (GFP). All of the vectors were packaged in the University of Iowa Gene Transfer Vector Core using the baculovirus system.
Physiological Recordings
RA mice and NT mice were anesthetized and instrumented with radiotelemetry transmitters. After a 14-day recovery, mice underwent ICV injection with 100 nL of adeno-associated virus (AAV)-PRR-shRNA or AAV-enhanced GFP (eGFP). BP was continuously recorded in conscious mice for 2 weeks. Autonomic function was assessed by determining BP or heart rate response to ␤-receptor blockade, muscarinic receptor blockade, and ganglionic blockade. Spontaneous baroreflex sensitivity (SBRS) was calculated using the "sequence method."
RNA Isolation and Real-Time RT-PCR
Brain nuclei, including the subfornical organ (SFO), paraventricular nucleus (PVN), nucleus of the tractus solitarius (NTS), and rostral ventrolateral medulla (RVLM), were micropunched from NT and RA mice to isolate total RNA. Specific primers for mouse PRR, mouse AT 1 receptor, mouse AVP, and, as an internal control, mouse GAPDH, were designed using PrimerQuest Software (Integrated DNA Technologies, Coralville, IA). The expression levels of targeted mRNAs were normalized based on the expression levels of GAPDH mRNA.
Immunofluorescence
Brain tissues were harvested and processed for PRR, AT 1 receptor, neuron-specific nuclear protein, 12 and glial fibrillary acidic protein 13 staining. Quantification was performed using National Institutes of health Image J software in a blinded manner.
Western Blot Analysis
Brain tissues were harvested and lysed. Protein lysates (25 g) were used for SDS-PAGE and blotting. Quantification was performed using National Institutes of Health Image J software in a blinded manner. The expression levels of targeted proteins were normalized based on the expression levels of ␤-actin protein.
ELISA
Peptide was extracted and concentrated from plasma using a Sep-Pak extraction kit (Waters Corporation). Plasma vasopressin concentrations were measured using AVP Fluorescent Immunoassay kit (Phoenix Pharmaceuticals).
Statistical Analysis
Data are expressed as meanϮSEM and analyzed by Student t test (2 groups) or 2-way ANOVA (multiple groups) followed by a Bonferroni post hoc test to compare replicate means when appropriate. Statistical comparisons were performed using Prism5 (GraphPad Software). Differences were considered statistically significant at PϽ0.05.
Results

PRR Is Expressed in Neurons and Upregulated in Ang II-Dependent Hypertensive Mice
Double immunostaining for PRR and neuron-specific nuclear protein or glial fibrillary acidic protein revealed that the PRR was mainly located in neurons ( Figure 1A through 1F). The PRR was detected throughout the brain in cardiovascular regions including the SFO, PVN, nucleus of raphe pallidus, NTS, and RVLM, as well as in noncardiovascular regions, such as brain cortex ( Figure 1G through 1L ). Sections incubated with preabsorbed peptide showed a complete lack of immunostaining ( Figure S2 , available in the onlineonly Data Supplement), confirming the specificity of PRR staining.
To examine PRR expression in normotensive and hypertensive conditions, coronal brain sections were immunostained with PRR antibody. Quantification of immunostaining showed that PRR expression was upregulated in the SFO and PVN of RA mice compared with NT mice (Figure 2A through 2C and 2E through 2G; PϽ0.01). PRR mRNA levels in the SFO and PVN were also significantly increased in the RA mice compared with NT mice (Figure 2D and 2H; PϽ0.01). Other areas of the brain, including the NTS, RVLM, and cortex, did not exhibit significant differences in PRR expression between RA and NT mice ( Figure S3 ). PRR mRNA expression was not uniform throughout the brain. PRR levels were significantly higher in the SFO and PVN and lower in the NTS compared with those in the cortex ( Figure S7 ).
AAV-PRR-shRNA Decreases PRR Expression Both in Neuronal Cells and SFO of the Brain
AAV-PRR-shRNA decreased PRR mRNA and protein expression by 60% to 70% compared with control virus in Neuro-2A cells (PϽ0.01; Figure 3A and 3B). We observed high levels of GFP fluorescence 3 days after virus infection in Neuro-2A cells ( Figure 3C ) and in the SFO ( Figure 3D ) after ICV administration of virus. A less intense GFP staining was observed in the ependymal cells of the lateral and third ventricular walls but not in other regions, including cortex, PVN, NTS, RVLM, median preoptic nucleus, vascular organ of the lamina terminalis, and area postrema ( Figure S4 ). PRR levels were measured 2 weeks after AAV-PRRshRNA or AAV-eGFP administration to further confirm PRR knockdown efficiency in vivo. ICV injection of AAV-PRRshRNA significantly reduced PRR mRNA levels in the SFO of both NT and RA mice compared with AAV-eGFP treatment (PϽ0.05; Figure 4A ). Although the PVN also exhibited upregulated PRR expression in RA mice, PRR mRNA levels were not significantly decreased (Pϭ0.341) by AAV-PRRshRNA ( Figure 4B ).
Brain-Targeted PRR Knockdown Attenuates Hypertension in RA Mice
RA mice with AAV-eGFP exhibited higher mean arterial BP compared with NT mice (PϽ0.05). AAV-PRR-shRNA significantly reduced mean arterial BP (PϽ0.05) in RA mice compared with control virus. PRR knockdown did not alter BP in NT mice ( Figure 5A ). RA mice exhibited a lower SBRS (1.5Ϯ0.1 ms/mm Hg) than NT mice (3.2Ϯ0.3 ms/mm Hg; PϽ0.05) after AAV-eGFP injection. PRR knockdown markedly improved SBRS in RA mice (2.2Ϯ0.2 ms/mm Hg; PϽ0.05); however, it did not affect SBRS in NT mice ( Figure 5B ). RA mice exhibited significantly higher cardiac ( Figure 5C ) and vasomotor ( Figure 5D ) sympathetic tone (⌬ heart rate to propranolol: Ϫ146Ϯ27 versus Ϫ42Ϯ6 bpm and ⌬ mean arterial BP to chlorisondamine: Ϫ75.9Ϯ1.2 versus Ϫ38.2Ϯ1.4 mm Hg; PϽ0.05) than NT mice with AAV-eGFP injection. AAV-PRR-shRNA significantly decreased cardiac and vasomotor sympathetic tone (⌬ heart rate: Ϫ91Ϯ17 bpm and ⌬ mean arterial BP: Ϫ58.6Ϯ6.6 mm Hg; PϽ0.05) in RA mice; however, AAV-PRR-shRNA did not alter sympathetic tone in NT mice. Parasympathetic tone (response to methylatropine) and intrinsic heart rate (response to methylatropine and propranolol) were not altered in any of the groups ( Figure 5E and 5F).
PRR Knockdown Decreases AT 1 Receptor and AVP Level in the RA Mice
To elucidate the possible mechanisms involved in the attenuation of hypertension after brain PRR knockdown, we investigated AT 1 receptor, plasma AVP, and AVP mRNA levels in the PVN. AT 1 receptor mRNA levels were significantly higher in RA compared with those of NT mice ( Figure  6A ; PϽ0.01). AAV-PRR-shRNA significantly reduced AT 1 receptor mRNA levels in RA mice compared with control virus but not in NT mice. Western blot data also revealed upregulated AT 1 receptor expression in RA mice ( Figure 6B ; PϽ0.01). PRR knockdown significantly decreased AT 1 receptor expression in RA mice but had no effect on NT mice. Plasma AVP and AVP mRNA levels in the PVN were increased in the RA mice ( Figure 6C and 6D) . AAV-PRRshRNA significantly reduced AVP mRNA levels in the PVN and plasma levels in RA mice (PϽ0.05) but not in NT mice.
Discussion
Although previous studies have shown the importance of the PRR in diabetic nephropathy, 10 cardiac fibrosis, and heart failure, 11 the physiological and pathophysiological roles of the PRR in the central nervous system remain largely unknown. The present study reveals that PRR protein is highly expressed in neurons and is upregulated in the SFO and PVN in Ang II-dependent hypertensive mice. Furthermore, we found that PRR knockdown in the brain significantly decreases BP in RA mice, which is associated with a decrease in sympathetic tone and improvement of SBRS. Our results also show that PRR knockdown is associated with downregulation of the AT 1 receptor and reduction of AVP levels in RA mice, suggesting a potential new mechanism for PRR in the central BP regulation.
In the present study, we demonstrated that the PRR protein was primarily expressed in neurons in both cardiovascular 
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and noncardiovascular regions. Although brain renin activity is below the detection threshold of most standard assays, renin and prorenin mRNA are expressed in the neurons of regions controlling cardiovascular function. 14 In addition, circulating renin can reach the brain via the circumventricular organs that lack a blood-brain barrier, interacting with PRR located in these areas. Because the PRR binds both renin and prorenin leading to Ang II production, the finding of PRR in the brain provides additional evidence for the presence of a functional brain RAS. Although a recent study from Batenburg et al 15 challenged the possibility of prorenin interaction with PRR in non-(pro)renin synthesizing organs, this interaction might occur in prorenin-synthesizing tissues like brain, as showed in Figure S8 . Our data indicate that PRR is upregulated in the SFO and PVN of RA mice. The upregulated PRR may be attributed to higher Ang II levels in the transgenic mice. 16 In fact, Siragy and Huang 17 demonstrated that AT 1 receptor blockade decreases PRR expression in diabetic rats, supporting a role for Ang II in regulating PRR expression in vivo. In addition, we found that Ang II stimulated PRR mRNA expression in neuronal cells, which could be completely blocked by the AT 1 receptor blocker losartan ( Figure S6 ). Previous studies have shown that ICV administration of the viral vectors successfully infects the SFO. [18] [19] [20] Thus, in this study, we used ICV injection to deliver the AAV. By tracing GFP expression and measuring PRR levels, we found that the virus profoundly infected the SFO 2 weeks after injection. The dominant expression of GFP is probably attributed to the proximity of the ICV injection site to the SFO. In addition, because of the tight junction between the ependymal cells covering the SFO, 21 there might be some transport mechanisms responsible for uptake of the ICV-injected virus into this site.
To clarify the role of the PRR in BP regulation, we delivered AAV-PRR-shRNA into the mouse brain. Our data provide novel evidence that PRR knockdown in the brain attenuated hypertension, which was associated with improvement of SBRS and decrease in sympathetic tone. In contrast, PRR knockdown did not affect BP in normotensive mice. These findings are consistent with a previous study showing that PRR knockdown in supraoptic nuclei (SON) of the spontaneously hypertensive rats is associated with attenuation of hypertension development without affecting BP of normotensive control rats. 22 The nonalteration of BP in normotensive mice after PRR knockdown could be attributed to normal PRR activity and redundant mechanisms in maintaining BP in physiological conditions. In this study, we found that PRR expression was also upregulated in the PVN of RA mice. The role of the PVN in Ang II-dependent hypertension has been well documented. 23 We also noticed that ICV injection of AAV-PRR-shRNA did not completely normalize BP in the RA mice, indicating a possible role for PRR in the PVN in this model.
Brain AT 1 receptor is well known for stimulating sympathetic tone leading to the development of hypertension. [24] [25] [26] We observed that brain-targeted PRR knockdown reduced AT 1 receptor expression in the SFO. Although the exact mechanism by which the PRR regulates the AT 1 receptor remains unknown, the interaction between the 2 receptors tends to appear in pathological conditions, because the AT 1 receptor does not decrease in NT mice after PRR knockdown. A previous study showed that brain RAS activation enhances AVP release, which suggests chronically increased AVP as a possible mechanism of the elevated BP in RA mice. 24 Recently, it was reported that PRR knockdown in the SON decreases plasma AVP level associated with attenuation of hypertension in the spontaneously hypertensive rat. 22 The reduced synthesis and subsequent release of AVP after PRR knockdown observed in our study indicate that this might be another physiological mechanism for the contribution of PRR to BP regulation.
Perspectives
The identification of neural PRR as a potential activator of AT 1 receptor and AVP release suggests a novel mechanism contributing to the development of hypertension. Knockdown of the PRR in the central nervous system reduces BP and Continuously telemetric blood pressure (BP) was recorded in conscious nontransgenic (NT) and RA mice for baseline and after ICV injection (A). Spontaneous baroreflex sensitivity (SBRS) was calculated using the sequence method (B). Cardiac sympathetic tone (C), vasomotor sympathetic tone (D), parasympathetic tone (E), and intrinsic heart rate (F) were determined after administration of propranolol, chlorisondamine, and methylatropine; nϭ4 per group. *PϽ0.05 vs NT mice with adeno-associated virus (AAV)-enhanced green fluorescent protein (eGFP). #PϽ0.05 vs RA mice with AAV-eGFP (2-way ANOVA).
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improves autonomic function in hypertensive mice and is associated with the downregulation of the AT 1 receptor. This finding is of importance because blockade of the AT 1 receptor has been proven an effective way to treat hypertension. PRR blockade in the central nervous system may represent a novel approach for the treatment of neurogenic hypertension. Plasma vasopressin Enzyme-Linked Immuno Sorbent Assay was performed to determine the plasma vasopressin concentrations in NT and RA mice with AAV-PRR-shRNA or AAV-eGFP injection. Mice (n=5/group) were decapitated, and trunk blood was collected in chilled tubes containing EDTA. Peptide was then extracted and concentrated from plasma using a Sep-pak extraction kit (Waters). Plasma vasopressin concentration was then measured using an AVP Fluorescent Immunoassay kit (Phoenix Pharmaceuticals) following the company's instruction. Briefly, samples were incubated with primary antibody in the secondary coated immunoplate at 4 °C overnight. This was followed by incubation with biotinylated peptide at room temperature for 1.5 hours. After sufficient washing for 3 times, streptavidin-horseradish peroxidase was added into the plate and incubated for at room temperature. At the end of the protocol, substrate solution was added for the generation of fluorescence. The relative fluorescence unit was measured by a fluorescence reader with wavelength 340nm for excitation and 405nm for emission. showed strong bands at 46 kD for prorenin and thin bands at 38kD for matured renin.
